PM-02 CONDITIONAL INACTIVATION OF SMARCB1 IN P0 PERMISSIVE MOUSE CELLS GENERATES RHABDOID TUMORS IN THE PERIPHERAL NERVOUS SYSTEM AND IN THE BRAIN

by Vitte, Jeremie, Chareyre, Fabrice, Stemmer-Rachamimov, Anat, Judkins, Alexander, Giovannini, Marco
Published in Neuro Oncol (2015)

Timing of Smarcb1 and Nf2 inactivation determines schwannoma versus rhabdoid tumor development

by Vitte, Jeremie, Gao, Fuying, Coppola, Giovanni, Judkins, Alexander R., Giovannini, Marco
Published in Nat Commun (2017)

TMOD-15. SPATIOTEMPORAL LOSS OF SMARCB1 IN EARLY NEURAL CREST LINEAGE LEADS TO DIFFERENT MOLECULAR SUBTYPES OF RHABDOID TUMORS

by Vitte, Jeremie, Gao, Fuying, Coppola, Giovanni, Judkins, Alexander R, Giovannini, Marco
Published in Neuro Oncol (2019)

Refined Characterization of the Expression and Stability of the SMN Gene Products

by Vitte, Jérémie, Fassier, Coralie, Tiziano, Francesco D., Dalard, Cécile, Soave, Sabrina, Roblot, Natacha, Brahe, Christine, Saugier-Veber, Pascale, Bonnefont, Jean Paul, Melki, Judith
Published 2007

Deletion of Murine Smn Exon 7 Directed to Liver Leads to Severe Defect of Liver Development Associated with Iron Overload

by Vitte, Jérémie M., Davoult, Bénédicte, Roblot, Natacha, Mayer, Michèle, Joshi, Vandana, Courageot, Sabrina, Tronche, François, Vadrot, Jacqueline, Moreau, Marie Helene, Kemeny, François, Melki, Judith
Published 2004

mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma

by Giovannini, Marco, Bonne, Nicolas-Xavier, Vitte, Jeremie, Chareyre, Fabrice, Tanaka, Karo, Adams, Rocky, Fisher, Laurel M., Valeyrie-Allanore, Laurence, Wolkenstein, Pierre, Goutagny, Stephane, Kalamarides, Michel
Published 2014

MODL-13. GENETICALLY ENGINEERED PIG MODEL OF RHABDOID TUMOR PREDISPOSITION SYNDROME-1

by Na, Brian, Rubinstein, C Dustin, Meudt, Jennifer J, Biegel, Jaclyn A, Judkins, Alexander R, Lehman, Brent P, Reichert, Jamie L, Vitte, Jeremie, Shanmuganayagam, Dhanansayan, Giovannini, Marco
Published in Neuro Oncol (2020)

Rac1-mediated DNA damage and inflammation promote Nf2 tumorigenesis but also limit cell cycle progression

by Shi, Yuhao, Bollam, Saumya R., White, Shannon M., Laughlin, Sean Z., Graham, Garrett T., Wadhwa, Mandheer, Chen, Hengye, Nguyen, Chan, Vitte, Jeremie, Giovannini, Marco, Toretsky, Jeffery, Yi, Chunling
Published in Dev Cell (2016)

Expanding the mutational spectrum of LZTR1 in schwannomatosis

by Paganini, Irene, Chang, Vivian Y, Capone, Gabriele L, Vitte, Jeremie, Benelli, Matteo, Barbetti, Lorenzo, Sestini, Roberta, Trevisson, Eva, Hulsebos, Theo JM, Giovannini, Marco, Nelson, Stanley F, Papi, Laura
Published in Eur J Hum Genet (2015)

TMOD-23. PRECLINICAL DRUG EVALUATION IN A GENETICALLY ENGINEERED MINIPIG MODEL OF NEUROFIBROMATOSIS TYPE 1

by Osum, Sara, Stemmer-Rachamimov, Anat, Widemann, Brigitte, Dombi, Eva, Vitte, Jeremie, Dahiya, Sonika, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Gutmann, David, Giovannini, Marco, Moertel, Christopher, Largaespada, David, Watson, Adrienne
Published in Neuro Oncol (2019)

Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2

by Tanaka, Karo, Eskin, Ascia, Chareyre, Fabrice, Jessen, Walter J., Manent, Jan, Niwa-Kawakita, Michiko, Chen, Ruihong, White, Cory H., Vitte, Jeremie, Jaffer, Zahara M., Nelson, Stanley F., Rubenstein, Allan E., Giovannini, Marco
Published in Clin Cancer Res (2013)

Update From the 2011 International Schwannomatosis Workshop: From Genetics to Diagnostic Criteria

by Plotkin, Scott R., Blakeley, Jaishri O., Evans, D. Gareth, Hanemann, C. Oliver, Hulsebos, Theo J.M., Hunter-Schaedle, Kim, Kalpana, Ganjam V., Korf, Bruce, Messiaen, Ludwine, Papi, Laura, Ratner, Nancy, Sherman, Larry S., Smith, Miriam J., Stemmer-Rachamimov, Anat O., Vitte, Jeremie, Giovannini, Marco
Published 2013

Parkin Deficiency Delays Motor Decline and Disease Manifestation in a Mouse Model of Synucleinopathy

by Fournier, Margot, Vitte, Jérémie, Garrigue, Jérôme, Langui, Dominique, Dullin, Jean-Philippe, Saurini, Françoise, Hanoun, Naïma, Perez-Diaz, Fernando, Cornilleau, Fabien, Joubert, Chantal, Ardila-Osorio, Héctor, Traver, Sabine, Duchateau, René, Goujet-Zalc, Cécile, Paleologou, Katerina, Lashuel, Hilal A., Haass, Christian, Duyckaerts, Charles, Cohen-Salmon, Charles, Kahle, Philipp J., Hamon, Michel, Brice, Alexis, Corti, Olga
Published 2009

Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1

by Isakson, Sara H., Rizzardi, Anthony E., Coutts, Alexander W., Carlson, Daniel F., Kirstein, Mark N., Fisher, James, Vitte, Jeremie, Williams, Kyle B., Pluhar, G. Elizabeth, Dahiya, Sonika, Widemann, Brigitte C., Dombi, Eva, Rizvi, Tilat, Ratner, Nancy, Messiaen, Ludwine, Stemmer-Rachamimov, Anat O., Fahrenkrug, Scott C., Gutmann, David H., Giovannini, Marco, Moertel, Christopher L., Largaespada, David A., Watson, Adrienne L.
Published in Commun Biol (2018)

Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2–associated schwannomas reveals differences in efficacy and drug resistance development

by Fuse, Marisa A, Dinh, Christine T, Vitte, Jeremie, Kirkpatrick, Joanna, Mindos, Thomas, Plati, Stephani Klingeman, Young, Juan I, Huang, Jie, Carlstedt, Annemarie, Franco, Maria Clara, Brnjos, Konstantin, Nagamoto, Jackson, Petrilli, Alejandra M, Copik, Alicja J, Soulakova, Julia N, Bracho, Olena, Yan, Denise, Mittal, Rahul, Shen, Rulong, Telischi, Fred F, Morrison, Helen, Giovannini, Marco, Liu, Xue-Zhong, Chang, Long-Sheng, Fernandez-Valle, Cristina
Published in Neuro Oncol (2019)